Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 18, 2026.

60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis

David R Grattan

Journal of Endocrinology · 2015 · Review

doi:10.1530/joe-15-0213

Abstract

The hypothalamic control of prolactin secretion is different from other anterior pituitary hormones, in that it is predominantly inhibitory, by means of dopamine from the tuberoinfundibular dopamine neurons. In addition, prolactin does not have an endocrine target tissue, and therefore lacks the classical feedback pathway to regulate its secretion. Instead, it is regulated by short loop feedback, whereby prolactin itself acts in the brain to stimulate production of dopamine and thereby inhibit its own secretion. Finally, despite its relatively simple name, prolactin has a broad range of functions in the body, in addition to its defining role in promoting lactation. As such, the hypothalamo-prolactin axis has many characteristics that are quite distinct from other hypothalamo-pituitary systems. This review will provide a brief overview of our current understanding of the neuroendocrine control of prolactin secretion, in particular focusing on the plasticity evident in this system, which keeps prolactin secretion at low levels most of the time, but enables extended periods of hyperprolactinemia when necessary for lactation. Key prolactin functions beyond milk production will be discussed, particularly focusing on the role of prolactin in inducing adaptive responses in multiple different systems to facilitate lactation, and the consequences if prolactin action is impaired. A feature of this pleiotropic activity is that functions that may be adaptive in the lactating state might be maladaptive if prolactin levels are elevated inappropriately. Overall, my goal is to give a flavour of both the history and current state of the field of prolactin neuroendocrinology, and identify some exciting new areas of research development.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

When Geoffrey Harris wrote his influential monograph on ‘Neural Control of the Pituitary Gland’, it was already apparent that prolactin, or ‘lactogenic hormone’ as he referred to it, might be controlled differently to the other adenohypophyseal hormones. Harris convincingly built the case that humeral factors from the hypothalamus control secretion of anterior pituitary hormones, correctly predicting the existence of hypothalamic ‘releasing factors’ that mediate the neural control of pituitary secretions. Despite the clear evidence that neural stimuli (such as suckling) could stimulate prolactin secretion, however, Harris noted that cutting the pituitary stalk did not abolish lactation, leading to the inevitable conclusion that a hypothalamic ‘prolactin-releasing factor’ was not necessary to stimulate prolactin secretion. Indeed, it was subsequently shown in hypophysectomised rats that ectopic pituitary grafts were able to maintain corpus luteum function and lactation, demonstrating hypothalamic-independent secretion of prolactin from the grafts. At first impression, this appeared to contradict Harris' principle of neural control of the anterior pituitary. But further observations identified the fact that hypothalamic regulation was indeed critical for normal prolactin secretion, as Harris predicted, but that the mode of control was different. Everett found that while pituitaries located away from the hypothalamus would induce pseudopregnancy, a marker of elevated prolactin secretion in rodents, normal cycles (and therefore normal low levels of prolactin) would resume if transplanted pituitaries were re-vascularised by portal vessels under the median eminence. Two groups independently demonstrated that extracts of the median eminence/infundibular region could inhibit prolactin secretion from anterior pituitary cells in vitro. Subsequently, it was shown that median eminence lesions or destruction of the pituitary stalk resulted in elevated prolactin secretion (accounting for the pseudopregnancies described earlier by Everett). Thus, it was proven that the hypothalamus was essential for the regulation of prolactin secretion, but that it primarily exerted an inhibitory influence.

This brief review will summarise our current understanding of the hypothalamic control of prolactin secretion, and the neuroendocrine functions of prolactin, highlighting (admittedly selected) areas of current research interest. From the somewhat contrary beginnings previously introduced, the neural control of prolactin secretion, and indeed the whole hypothalamo-prolactin axis, continues to prove itself a bit different from other hypothalamo-pituitary systems. Not only is the hypothalamic regulation predominantly inhibitory, as opposed to stimulatory, it also involves a catecholamine neurotransmitter, dopamine, rather than the more typical peptide hypothalamic hormones involved in regulating all other pituitary systems. Prolactin is also the only anterior pituitary hormone that does not have an endocrine target tissue, and therefore lacks a classical hormonal feedback system. It is regulated, instead, by a short loop feedback whereby prolactin itself stimulates the secretion of the inhibitory factor, dopamine. Finally, despite its rather simple and one-dimensional name, prolactin does much more than simply PROmote LACTation. It is now recognised as a pleiotrophic hormone with arguably the widest range of physiological actions of any extracellular signalling molecule in the body.

Dopamine as a prolactin-inhibitory hormone

Even after the clear demonstration of inhibitory regulation of prolactin secretion in the 1950s, the search for the inhibitory hormone mediating this action was controversial. All hypothalamic hormones identified to date had been peptides, and the expectation was that ‘prolactin-inhibitory factor’ would also be a peptide. Initial clues that this might not be the case came from observations that drugs such as reserpine, which depletes endogenous catecholamines, induced pseudopregnancy in rats, indicative of elevated prolactin. It was assumed, however, that the functional role of catecholamines were as neurotransmitters acting in the hypothalamus to regulate the release of a hypothalamic hormone. Based on the evidence of dopaminergic nerve terminals in the median eminence, McLeod proposed that dopamine may be released into the pituitary portal system, and thereby acting as a hypothalamic hormone (as distinct from its neurotransmitter role in other systems). He demonstrated that dopaminergic agonists were effective at suppressing prolactin secretion in vivo, and perhaps more importantly, that dopamine could inhibit prolactin secretion from isolated pituitary glands. Dopamine was subsequently detected in the pituitary portal blood, and Porter's group (and others) found that variations of levels of dopamine in the portal blood accounted for changes in prolactin secretion in various physiological conditions. Dopamine receptors were identified on lactotroph cells in the anterior pituitary. The observation that mice lacking the dopamine D2 receptor are hyperprolactinemic, clearly demonstrated the critical role of dopamine in suppressing endogenous prolactin secretion (see Fig. 1).

The dopamine neurons that control prolactin secretion are located within the arcuate nucleus of the hypothalamus. While it seems likely that they serve functionally as a single population, these neurons have been subdivided into three sub-populations based on the anatomy of their projections: the tuberoinfundibular (TIDA), tuberohypophyseal (THDA), and periventricular hypophyseal (PHDA) dopaminergic neurons. TIDA neurons arise from the dorsomedial arcuate nucleus and project to the external zone of the median eminence. The other two populations have their cell bodies located slightly more rostrally, but their projections pass in the hypothalamo-hypophyseal tract through the median eminence to the hypophysis. The THDA neurons originate in the rostral arcuate nucleus and project to the intermediate and neural lobes of the pituitary gland, while the PHDA neurons originate in the periventricular nucleus, with axons terminating in the intermediate lobe. The TIDA neurons produce the classical hypothalamic hormone secretion into the pituitary portal blood vessels, while THDA and PHDA neurons contribute to basal regulation of prolactin secretion, after transport of dopamine to the anterior pituitary gland through short portal vessels from the neurohypophysis. While anatomically distinct, there is considerable overlap in their dendritic fields, and all three populations appear to be regulated similarly. For example, all are stimulated by prolactin. Hence, it is reasonable to consider them as a functional unit of prolactin-inhibiting neurons.

Electrophysiological studies of hypothalamic dopamine neurons in the rat have described TIDA neurons as exhibiting a robust oscillation between hyperpolarized and depolarized states, with periodicity of about 20 s, and a spontaneous firing rate of ∼4 Hz during the depolarized ‘up-state’. Remarkably, the TIDA neurons were found to show a synchronous pattern of firing suggestive of an interconnected network, dependent on functional expression of gap junctions. Taking advantage of transgenic technologies to label dopaminergic neurons with fluorescent tags, studies of TIDA electrical activity have also been completed in brain slices from mice, showing a similar pattern of firing to that seen in the rat, although only a small proportion of TIDA neurons showed the phasic oscillations in this model. Importantly, one of these latter studies demonstrated that patterns of firing of an individual TIDA neuron were reflected in the pattern of dopamine release from the population, as measured using in vivo amperometry in the median eminence. These data support the concept postulated by, that the neurons act as a synchronous network to release dopamine in a pulsatile or phasic fashion.

Of the five dopamine receptors, the two members of the D2-like receptor family, D2 and D4 are found in the pituitary gland and it is through these D2-like receptors that dopamine acts to inhibit lactotroph cell function. Uniquely among anterior pituitary cells, lactotrophs display spontaneous electrical activity in the absence of hypothalamic stimulation and Ca2+ influx through voltage-gated Ca2+ channels (VGCC) stimulates to prolactin secretion. This accounts for the high levels of basal prolactin secretion, and is consistent with a regulatory mechanism primarily based on inhibition. Dopamine inhibits calcium influx resulting in membrane hyperpolarisation and reduced prolactin secretion. In addition to its effect on secretion, dopamine-induced suppression of adenylate cyclase leads to a reduction in prolactin gene expression. Dopamine also has a significant role to regulate lactotroph proliferation, as demonstrated in cultures of pituitary cells, as well as in vivo by suppression of oestradiol-induced proliferation. When dopamine levels are increased, such as caused by the loss of the dopamine transporter, there is a severe post-natal reduction in lactotroph proliferation leading to a dramatic reduction in the number of lactotrophs by 8 weeks of age. In contrast, there is marked lactotroph hyperplaisia following loss of the D2 receptor, leading to the formation of prolactinomas. This is exacerbated by age, and more prevalent in females than males. A bias towards lactotroph hyperplasia and more rapid generation of pituitary tumours in females may be expected from the direct actions of estradiol to stimulate prolactin production by lactotrophs, but this may not be the sole factor leading to the increased female hyperplasia. Gonadectomy has been shown to reduce lactotroph hyperplasia and tumour formation in D2 knockout mice, but that this could not be fully rescued by estradiol replacement, suggesting that ovarian factors other than estradiol may contribute to the proliferation of lactotrophs.

Prolactin regulation of dopamine neurons: short loop feedback

As previously mentioned, the hypothalamo-prolactin system does not have a specific endocrine target, and therefore lacks the classical hormone-mediate negative feedback pathway described for all other anterior pituitary hormones. Nevertheless, it is still regulated in a negative feedback manner, with prolactin itself providing the afferent signal in a process known as short-loop feedback. The presence of prolactin receptors on dopamine neurons was predicted by early neurochemical studies that showed that exogenous prolactin stimulated hypothalamic dopamine synthesis and turnover, increased dopamine metabolism in the median eminence and promoted dopamine secretion into the pituitary portal blood. In contrast, hypoprolactinemia induced by administration of dopamine agonists resulted in suppression of dopamine secretion, indicating that the basal activity of these neurons is dependent on the endogenous levels of prolactin present in the blood. Using these biochemical indices of activity of TIDA neurons, the time course of prolactin action was described as having a ‘rapid’ component of increased activity observed 2–4 h after prolactin treatment, and a delayed component seen ∼12 h after prolactin treatment. More recent electrophysiological data has demonstrated even more rapid actions of prolactin on the electrical activity of TIDA neurons in mice or rats. These studies show that prolactin induces a fourfold increase in firing rate within seconds to minutes of application, acutely changing the firing pattern from a basal phasic pattern to a tonically active pattern. Hence, there seem to be multiple mechanisms of prolactin regulation of these dopamine neurons mediated over different time courses.

It was observed that prolactin feedback was markedly impaired in mice lacking the transcription factor STAT5b, likely through impairment in the long-term regulation of expression of the rate limiting enzyme in dopamine synthesis, tyrosine hydroxylase. While such an effect might account for the ‘delayed’ component of prolactin feedback, which requires protein synthesis, it is unlikely to account for more rapid components of short look feedback. The very rapid action revealed by electrophysiology appears to involve two components: a low voltage component from transient receptor potential (TRP)-like current and high voltage component from inhibition of a Ca2+-dependent BK-type K+ current, with the latter component being wortmannin sensitive, suggesting an involvement of the PI3K pathway. The slower component, originally described as ‘rapid’ in neurochemical experiments, with a time course of minutes to hours, likely involves prolactin-induced serine phosphorylation of tyrosine hydroxylase, resulting in increased enzyme activity. Together, these three layers of prolactin regulation of hypothalamic dopamine neurons provides a tight homeostatic control, with prolactin rapidly increasing the firing rate of these neurons to induce increased dopamine secretion into the portal blood and rapid suppression of further prolactin secretion from the lactotroph. At the same time, slower but more prolonged changes in tyrosine hydroxylase phosphorylation and transcriptional events to maintain changes in tyrosine hydroxylase gene transcription serve to regulate neuronal function over a much longer time-course, priming the neurons for continued responses to changes in prolactin levels.

For endogenous prolactin to function in the short-loop feedback manner, previously described, one important consideration is how this relatively large (197–199 amino acids; 21 kDa) polypeptide hormone crosses the blood brain barrier to gain access to the dopamine neurons. While it is possible that the arcuate nucleus/median eminence region may have an incomplete blood-brain barrier such that hormones can directly access to neurons in this area, it seems unlikely that this is the major mechanism by which prolactin regulates the hypothalamic dopamine neurons. Indeed, systemic administration of prolactin has been shown to simultaneously activate neurons throughout the hypothalamus, not simply in the arcuate nucleus. There is clear evidence that systemic prolactin crosses the blood brain barrier through a saturable, carrier-mediated transport system. As a result, prolactin levels in the cerebrospinal fluid parallel changes in prolactin in the peripheral circulation. Because of the high levels of prolactin receptor expression and prolactin binding seen in the choroid plexus, it has been widely assumed that the prolactin receptor might mediate prolactin entry into the cerebrospinal fluid. However, we have recently shown that prolactin transport into the brain is independent of the prolactin receptor, occurring just as well in prolactin receptor knockout mice (Brown RSE, Wyatt AK, Herbison RE, Knowles PJ, Ladyman SR, Binart N, Banks WA & Grattan DR, unpublished observations). Hence, precise mechanism that translocates prolactin from the blood into the CSF remains to be determined.

Plasticity in prolactin feedback during lactation

In order to support a period of hyperprolactinemia during lactation, and thereby promote the milk production that is essential to this state, there is an apparent loss of sensitivity of the short-loop feedback system during late pregnancy and lactation. This is a remarkable example of adaptive plasticity within a neuroendocrine control network, allowing a sustained period of high prolactin secretion to be maintained unencumbered by a regulatory feedback pathway (see Fig. 2). The mechanisms mediating this adaptive response are only recently becoming elucidated. Up until late pregnancy in rodents, normal negative feedback regulation of prolactin secretion dominates, as previously described, but high levels of placental lactogens are produced. As placental lactogen binds to and activates prolactin receptors, this mimics prolactin action and bypasses the feedback inhibition to ensure that prolactin responsive functions are highly stimulated at this time. Activity of hypothalamic dopamine neurons is maintained by the presence of placental lactogen, so pituitary prolactin secretion is low. Despite the continued presence of placental lactogens, however, there is a decrease in activity of the dopamine neurons during late pregnancy associated with a nocturnal surge in pituitary prolactin secretion immediately before parturition. Hypothalamic dopamine neurons apparently no longer release dopamine in response to prolactin or placental lactogen at this time, rendering the short-loop negative feedback system functionally inactive. This adaptation persists into lactation, and dopamine secretion remains low throughout this period of elevated prolactin secretion. This is an important adaptation, because prolactin is required for milk production and maternal behaviour at this time.

There is a highly coordinated release of prolactin during lactation, caused by the suckling stimulus. This is associated with a decrease in dopamine turnover in hypothalamic dopamine neurons and a profound suppression of tyrosine hydroxylase mRNA levels. The original perception that hypothalamic dopamine neurons show a ‘loss of response’ to prolactin at this time has proved to be incorrect. In fact, prolactin receptor expression in the dopamine neurons is maintained, and acute electrophysiological responses to prolactin persist in lactation. Downstream of the prolactin receptor, however, there is a change in the cellular response. Serine 40 phosphorylation of tyrosine hydroxylase in the median eminence is decreased, resulting in a reduction in the activity of this enzyme (and a reduction in dopamine synthesis). Strikingly, there is a disconnection between neuronal firing and dopamine release at the median eminence. Even though the electrophysiological response to prolactin is unchanged, there is no longer detectable release of dopamine in the median eminence. Prolactin-induced activation of STAT5b in dopamine neurons is reduced during lactation, potentially mediated by an up-regulation of endogenous inhibitors of STAT signaling, the suppressors of cytokine signaling (SOCS) proteins. At the same time as the loss of dopamine secretion, there is an increase in met-enkephalin expression in the dopamine neurons, and it seems possible that elevated prolactin may drive this met-enkephalin expression. Hence, the neurons essentially change their phenotype, changing from being dopaminergic to enkephalinergic. As they still respond electrophysiologically to prolactin, they may be mediating a completely different function of prolactin in the brain during lactation.

It is interesting to note that while the suckling-induced prolactin secretion could be consistent with the ‘dopamine withdrawal’ or ‘disinhibition’ model of prolactin secretion, previously discussed, the chronic reduction in dopamine output seen during lactation complicates this interpretation. If dopamine production is lost, as implied in the data of, how can suckling cause an acute increase in prolactin secretion through dopamine withdrawal? Perhaps this is evidence that a suckling-induced ‘prolactin-releasing factor’ may be involved in stimulating prolactin secretion at this time (see further discussion of prolactin-releasing factors in the following section). It is well established that enkephalin can promote prolactin secretion, and while most evidence suggests that this effect is mediated centrally through regulation of TIDA neurons, it can also act in the pituitary gland to antagonize dopaminergic inhibition of lactotrophs. Could the lactation-specific release of enkephalin from TIDA neurons be functioning as a prolactin-releasing factor, either in the classical sense, by regulating lactotroph function via the portal blood, or through a more local effect on TIDA neurons within the median eminence? Either way, the idea that prolactin might be promoting its own secretion through the same neurons that normally inhibits its secretion, essentially switching from negative to positive feedback at a time when high levels of prolactin are required, is a provocative one worthy of further investigation.

Some significant insight has been provided by recent advances in mapping the neuronal pathways conveying the sucking stimulus through to specific neuronal populations within the hypothalamus. A direct neuronal pathway is involved, transmitting the somatosensory afferent information from the nipple via the spinal cord to the hypothalamus. Recent evidence suggests that there is a direct pathway from the subparafascicular nucleus and posterior thalamus to the ventrolateral arcuate nucleus, possibly connecting with the dynorphin neurons located in this region. Neurons in this pathway express the peptide tuberoinfundibular peptide of 39 residues (TIP39), and this peptide may be a critical regulator of prolactin secretion in response to suckling, acting through the parathyroid hormone 2 receptor to suppress activity of TIDA neurons.

Role of a ‘prolactin-releasing factor’?

Ever since Harris' first proposal of the humeral control of the anterior pituitary gland, researchers have searched for a ‘prolactin-releasing factor’ to match that of other pituitary hormones. There have been some notable discoveries, but to date, convincing evidence for a physiological prolactin-releasing factor has not been forthcoming (for reviews, see, and ). Most of the factors that regulate prolactin secretion do so by directly or indirectly influencing dopamine secretion from the hypothalamic dopamine neurons. The best example of this is prolactin itself, which stimulates dopamine release to inhibit its own secretion (previously discussed). Other examples are opioid peptides, which are potent stimulators of prolactin secretion, and act predominantly through an inhibition of dopamine neurons. Alternatively, factors may stimulate prolactin secretion through an action on the pituitary gland. The ovarian steroid, estradiol, is an excellent example, acting on lactotrophs to increase prolactin gene expression and increase levels of prolactin released in response to other stimuli. Neither of these actions would classify as a hypophysiotrophic ‘prolactin releasing factor’, as defined by Harris. For this, the factor would need to be produced in the hypothalamus, be secreted into the portal blood, and act in the pituitary gland to stimulate prolactin secretion (and thereby oppose the actions of the hypothalamic inhibitory hormone).

The levels of prolactin achieved by administration of dopamine antagonists are as high as one would normally associate with prolactin release stimulated under physiological conditions, such as in response to the suckling stimulus. Thus, it would seem possible to account for most stimulated prolactin secretion simply by a process of disinhibition, removing the normal dopaminergic inhibitory control. However, whether such a total withdrawal of dopamine ever occurs in vivo is unlikely. There is continued interest in the possibility that a physiological ‘prolactin-releasing factor’ exists. Vasoactive intestinal polypeptide (VIP) may be the ancestral regulator of prolactin secretion, since it is the primary ‘prolactin-releasing factor’ in non-mammalian vertebrates, and it has stimulatory effects on prolactin secretion in mammals. However, while produced in both the hypothalamus and in the pituitary gland, it is unlikely that VIP acts as a hypophysiotrophic releasing factor, in the sense defined by Harris. It does not appear to be secreted into the portal system at levels higher than in the systemic circulation, nor is it present at elevated levels in the blood at all times that prolactin secretion is high. The same is probably true for a large number of factors that have been investigated as putative ‘prolactin releasing hormones’, including thyrotropin-releasing hormone, oxytocin, galanin, salsolinol, prolactin-releasing peptide and others (reviewed in, and ). Many of these factors may influence prolactin secretion, either from effects on hypothalamic dopamine neurons, or from effects on pituitary lactotrophs, but none have proven to meet the criteria to be considered hypothalamic hypophysiotrophic factors.

Freeman's group tackled this question by investigating whether changes in prolactin could be observed independently of dopaminergic inhibition. They observed that administration of the D2 antagonist domperidone induced different levels of prolactin secretion at different times of the day. Assuming that antagonism of dopamine was complete at each time point, they interpreted these data to demonstrate the existence of an ‘endogenous stimulatory rhythm’, where factors from the hypothalamus (including oxytocin and VIP) were promoting prolactin secretion at specific times in dependently of dopamine, but this stimulation was usually masked by the prevailing dopaminergic tone. Importantly, they also showed that endogenous stimuli that reduce dopamine input to the pituitary, such as suckling, could also reveal this stimulatory rhythm, promoting different levels of prolactin secretion at different times of the day. These data provide convincing evidence of dopamine-independent regulation of prolactin secretion, but cannot conclusively prove it is mediated by a ‘prolactin-releasing factor’. An alternative possibility is that endogenous circadian regulators within the pituitary gland might influence that amount of prolactin released at different times of the day. Circadian regulation of prolactin secretion has also been documented via melatonin actions in the pars tuberalis.

If there is a physiological ‘prolactin-releasing factor’, it remains elusive. One possible reason for this is that the stimulatory control exerted from the hypothalamus may not be a ‘classical’ system, as defined by Harris. In the late 1980s and early 1990s, there was a particularly well-developed story regarding a putative prolactin-releasing factor coming from a subpopulation of melanotrophs in the intermediate lobe of the pituitary, as opposed to the median eminence. This factor was originally discovered by,, who showed that surgical removal of the posterior pituitary (including the intermediate lobe) impaired the prolactin release in response to estradiol administration or suckling. This was subsequently supported by a number of other groups, with studies demonstrating reduced or absent prolactin secretion after removal of the neurointermediate lobe. Moreover, mice with secretory tumours of the intermediate lobe were hyperprolactinemic. Despite extensive effort at characterisation, particularly from the Ben-Jonathan group, the specific identity of this factor (or factors) has not been identified, although a number of known prolactin secretagogues (TRH, oxytocin, VIP) were excluded. Nevertheless, this highlights the possibility that ‘non classical’ prolactin releasing systems may remain to be discovered.

Based on the magnitude of prolactin release in response to dopamine inhibition, I have previously held the view that most prolactin release could be accounted for by a decrease in dopamine. Our new data showing that even after marked reductions in dopamine secretion during lactation in mice, there is a sustained ability to regulate prolactin secretion in response to suckling, however, has forced a re-think of this view. It would seem that other regulatory factors must be involved in the physiological regulation of prolactin secretion, particularly during lactation when it is most required. Whether one or more of these factors becomes the long sought ‘prolactin-releasing factor’ predicted by Harris remains an exciting area needing further investigation.

Regulation of prolactin secretion by estradiol

The ovarian steroid estradiol is arguably one of the most important regulators of prolactin secretion in several different physiological states. In the pituitary gland, estradiol is a major stimulator of prolactin secretion, although this is principally through a classical genomic regulation of prolactin gene expression, by increasing the number of lactotrophs and by modifying lactotroph responsiveness to other regulators, although a rapid non-genomic actions of estradiol stimulating prolactin secretion have been described. The TIDA neurons also express receptors for both estradiol (estrogen receptor alpha (ERα)) and progesterone, and gonadal steroids regulate prolactin secretion indirectly through actions on these neurons. These actions of estradiol are particularly important during the reproductive cycle and during pregnancy. The predominant direct action of estradiol on TIDA neurons is one of inhibition, suppressing TH expression and activity, and reducing secretion of dopamine into the portal blood, thereby facilitating prolactin secretion. The estradiol-induced proestrous prolactin surge is associated with a steroid-dependent decline in TIDA activity, with a prominent role for progesterone suppressing dopamine release during the plateau phase of the surge. Similarly, ovarian steroids play a critical role in controlling the twice-daily prolactin surges required to sustain luteal function pregnancy in rodents. The rising levels of estradiol during pregnancy are also critical to promoting prolactin secretion, particularly during late pregnancy, and to the plasticity in the TIDA neurons as previously described. In addition to regulation of prolactin secretion, estradiol may also regulate the cellular responses to prolactin. In the brain, many of the neurons expressing the prolactin receptor also express ERα. Estradiol may regulate prolactin receptor expression on neurons, and several of the actions of prolactin are dependent on the presence of estradiol. Thus, estradiol acts at multiple levels to both directly and indirectly regulate prolactin synthesis, secretion and action.

Neuroendocrine functions of prolactin

Prolactin was identified and named for its critical role in the physiology of lactation, and this remains its best-characterised function. Prolactin is indispensible for lactation. However, a vast array of additional functions has also been characterised. These have been thoroughly reviewed by Paul Kelly's group, who classified the functions under six broad headings: water and electrolyte balance, growth and development, endocrinology and metabolism, brain and behaviour, reproduction and immune regulation and protection. The breadth of potential functions is astounding and difficult to conceptualise into a theoretical framework. Many of the reported actions of prolactin appear to be redundant, as evidenced by the lack of a significant phenotype in the prolactin or prolactin-receptor knockout mice. This may simply be the evolutionary result of a phylogenically old signalling molecule being used for multiple adaptive roles in homeostasis. One can see examples where prolactin has subserved similar functions across many species. For example, in fish and amphibia, it is involved in electrolyte balance, and movement of ions and water across epithelial barriers. Perhaps this is not so different from inducing secretion of nutrients and electrolytes from an epithelial gland, as in the crop milk of pigeons, and the breast milk of mammals. Similarly, prolactin has been implicated in parental behaviour ranging from nest fanning in fish, through to incubation and brooding behaviour in birds, to lactation and maternal behaviour in mammals. When viewed from an evolutionary context, it seems logical that the nurturing parental behaviour actions of prolactin might have evolved in parallel with a nutrient synthesis and secretion role, providing an adaptive advantage of novel reproductive strategies.

There is insufficient space in this review to do justice to the wide range of potential prolactin-sensitive functions. Instead, I have taken the strategy of focusing on functions that are specifically regulated when endogenous prolactin levels are high. Apart from the estrogen-induced prolactin surge during the female reproductive cycle (which may not occur in all species, and the response to stress, which is transient and of low magnitude, prolactin levels are typically maintained at low levels as a consequence of the highly effective short loop negative feedback. The exception to this is pregnancy and lactation, where mammals exhibit at least three adaptations to ensure high levels of lactogenic hormone activity throughout these conditions (see Fig. 2). First, there is the production of placental lactogen and/or decidual prolactin, lactogens from reproductive tissues. These hormones act on the prolactin receptor, and therefore bypass the short-loop feedback regulation of the anterior pituitary gland to provide constantly elevated levels of lactogenic hormones throughout pregnancy. Secondly, there are the adaptive changes in feedback occurring in the maternal hypothalamic dopamine neurons, previously discussed, changing the manner in which they respond to prolactin, enabling high secretion to prolactin to be maintained from the maternal pituitary after the pregnancy-specific placental lactogens are lost at parturition. Thirdly, there is the hormone-dependent expression of maternal behavior, with the consequent suckling stimulus from the pups providing the most powerful stimulus to pituitary prolactin secretion that is known in mammals. As previously discussed, this might involve chronic and/or acute dopamine withdrawal, as well as the additional stimulus of an as yet unidentified ‘prolactin-releasing factor’ to maintain elevated levels of prolactin. Finally, we have recent evidence suggesting that transport of prolactin into the brain is increased during lactation (Brown RSE, Wyatt AK, Herbison RE, Knowles PJ, Ladyman SR, Binart N, Banks WA & Grattan DR, unpublished observations), suggesting that many of the CNS functions of prolactin might be further enhanced at this time. These multiple adaptive changes make a compelling argument to focus on pregnancy and lactation as the most critical time for prolactin actions in the body.

It is absolutely clear that these elevated levels of lactogenic hormones are required for development of the mammary gland during pregnancy and for milk production during lactation. The regulation of mammary function by prolactin is extensively reviewed elsewhere. It is important to recognize, however, that prolactin and placental lactogen are also able to act in a wide variety of other tissues in the body. The prolactin receptor is widely expressed in numerous body systems, including bone, adipose tissue, gut, reproductive tract, skin, immune system, pituitary and brain, and hence, when prolactin is elevated there is potential for a wide variety of systems to be influenced. In recent reviews, we have proposed the hypothesis that the wide range of potential actions of prolactin in the body make some collective sense if considered within the context of the physiological hyperprolactinemic state of pregnancy and lactation. These are complex and demanding processes for a mother, requiring multiple diverse systems to undergo adaptive changes to facilitate her successful transition from the non-pregnant into the maternal state. A selection of these adaptive changes, and a summary of the evidence that prolactin might influence the adaptive response, are outlined in Table 1. Here, prolactin can be considered as interoceptive sensory information for the body, informing it of its new physiological state. The changes it induces are adaptive, which means that the functions are unlikely to completely fail in the absence of prolactin action, but they might not perform optimally. This would account for the absence of widespread adverse phenotype in the prolactin receptor knockout mice. It is appropriate to point out that many of the associations shown in Table 1 are, at this stage, correlative only, and comprehensive investigation proving that prolactin may be mediating a particular adaptive change will require significant further work. Nevertheless, we have found this to be a useful construct for understanding why prolactin might be influencing such a wide range of biological function. We used to be concerned by the question of, ‘Why would there be over 300 physiological actions of prolactin?’ Now, we can consider each of the different tissues that express the prolactin receptor and ask the question, ‘Why might this tissue need to change its function during lactation?’

Comprehensive reviews of the wide range of actions of prolactin in the body are available elsewhere, as is our hypothesis regarding the role of prolactin in the physiological adaptation to pregnancy, and hence, I will not go into detail here. In the final section of this review, I would like to briefly highlight three selected examples from recent research. The first of these, the metabolic functions of prolactin, nicely illustrates the context previously outlined that prolactin is acting in a number of different tissues and cell types in the mother to facilitate adaptation to pregnancy or lactation. The second example, looking at prolactin effects on fertility, highlights how functions of prolactin that might be considered adaptive in a lactating female, might be maladaptive should high prolactin occur at an inappropriate time. The third example asks the question, ‘What is prolactin doing in the male?’ This example is used to acknowledge the fact that some of the known functions of prolactin do not comfortably fit into the conceptual framework previously presented.

Metabolic function of prolactin

This is, perhaps, the best example of the pleiotropic role of prolactin (defined to mean a single gene product, prolactin, exerting multiple seemingly diverse actions). Prolactin receptors are expressed on multiple tissues involved in metabolic regulation, including adipose tissue, liver, pancreas and the brain. It appears to play a broad role in both pancreatic and adipose development. In adipose tissue, prolactin is essential in adipogenesis and adipocyte differentiation, as well as modulating lipid metabolism. It also regulates the secretion is several adipokines, including stimulation of leptin and inhibition of adiponectin production. In the pancreas, it promotes growth of islets during development, and increases insulin expression and glucose-stimulated insulin secretion. It also increases expression of glucose transporter 2 and promotes glucose entry into the β-cells, resulting in enhanced activity of glucose-sensitive enzymes such as glucokinase. In both adipose tissue and pancreas, these actions are likely to be profoundly important during pregnancy and lactation. Lipid metabolism is altered, with lipid mobilisation from stores and utilisation in mamary gland promoted by prolactin. Adaptive changes in glucose homeostasis are also important in pregnancy. Maternal tissues develop insulin resistance to preferentially direct glucose to the fetal/placental compartment, and to ensure the maternal tissues continue to receive the nutrients required, there is increased demand for maternal insulin secretion, and glucose-stimulated insulin secretion increases. To adapt to this altered demand, there is significant proliferation of β-cells in the islets, enhanced insulin synthesis, and decreased threshold for glucose-stimulated insulin secretion, with prolactin playing a critical adaptive role in promoting these changes. Failure of this adaptive response results in gestational diabetes.

These peripheral actions of prolactin on metabolism are complemented by CNS actions of prolactin to promote appetite and potentially regulate glucose homeostasis. Systemic prolactin administration increases food intake in a variety of species, independent of potential effects on ovarian steroids. Thus, the elevated prolactin secretion is likely to contribute to the rapid increase in food intake during pregnancy and the extreme hyperphagia of lactation. Prolactin also induces functional leptin resistance, which would contribute to increased food intake, potentially mediating the well-established leptin resistance of pregnancy. Prolactin receptors are found in many of the nuclei involved in the homeostatic regulation of food intake, including the arcuate, ventromedial and paraventricular nuclei. However, prolactin receptors do not appear to be expressed in the arcuate neuropeptide Y (NPY) and proopiomelanocortin (POMC) neurons that regulate appetite. Hence, it seems likely that prolactin acts downstream of the arcuate neurons, such as at the paraventricular nucleus. Consistent with this hypothesis, localised injections of prolactin directly into the paraventricular nucleus stimulate food intake in a dose-dependent manner in female rats.

Thus, seemingly diverse actions of prolactin in multiple different cell types can be unified into a single adaptive function, which is metabolic adaptation to pregnancy, increasing energy availability to the mother and offspring. This is an example of the conceptual framework previously outlined, and it can be viewed as a positive, adaptive mechanism. Should hyperprolactinemia occur at an inappropriate time, however, then one might predict this could contribute to metabolic disorders. There is some evidence for this. While it is not universally observed, patients with hyperprolactinemia are prone to excessive weight gain, and normalisation of prolactin levels using dopamine agonists is associated with weight loss. Interestingly, genome-wide association studies have revealed that a common variant adjacent to the prolactin gene is associated with obesity suggesting that abnormalities in prolactin or prolactin signalling may contribute to human obesity.

Hyperprolactinemia and infertility

Hyperprolactinemia causes infertility in both males and females, and this provides an even more clear-cut example of a potentially adaptive function under certain conditions becoming clearly maladaptive in another situation. The mechanism by which prolactin inhibits the reproductive axis is not clear, but evidence suggests that prolactin impacts fertility through actions on GnRH neurons. In humans, hyperprolactinaemia is associated with a marked reduction in both the frequency and amplitude of LH pulses indicative of a change in GnRH pulses, and the suppression of LH pulsatility can be reversed by reducing serum prolactin concentrations to normal. While prolactin could exert effects in either the pituitary or gonad, pulsatile GnRH replacement can reverse the infertility induced by hyperprolactinaemia, suggesting a prolactin-induced suppression of GnRH release is the proximal cause of infertility. Similarly, prolactin suppresses both the frequency and amplitude of LH pulses in male and female rats and measurements of GnRH secretion into the portal blood have revealed prolactin-induced suppression of GnRH release. Furthermore, hyperprolactinaemia has been shown to prevent the castration-induced increase in GnRH mRNA expression in rats. Thus, although there is ample evidence that prolactin can act in the pituitary gland to suppress LH secretion, in animal models, as in clinical studies, the primary cause of infertility appears to be the suppression of the activity of GnRH neurons. This effect of prolactin is unlikely to be mediated directly by an action on GnRH neurons, as the majority of these neurons do not express the prolactin receptor. Thus, prolactin-induced inhibition of GnRH neurons must involve prolactin-sensitive afferents to these cells. Interestingly, most prolactin responsive neurons also express ERα, so prolactin may share a common mechanism of regulating GnRH with the negative feedback pathway mediated by estradiol. As such, kisspeptin neurons have emerged as the most likely intermediate regulators.

Since first being identified as essential for puberty in humans, kisspeptin neurons are now recognised as critical parts of the circuit regulating activity of the GnRH neurons that control fertility. Kisspeptin neurons may have an important role in mediating the suppressive effect of prolactin on fertility. Kisspeptin is the most potent stimulator of GnRH neuronal activity yet identified. In most mammalian species, there are two populations of kisspeptin neurons, with kisspeptin neurons in the rostral periventricular area of the third ventricle (RP3V) playing an essential role in enabling ovulation in rodents by activating GnRH neurons, while kisspeptin neurons in the arcuate nucleus are thought to be involved in the regulation of the basal pulsatile secretion of GnRH. Prolactin receptors are expressed in the majority of kisspeptin neurons in both populations, and prolactin has recently been shown to induce the phosphorylation of signal transducer and activator of transcription 5 (pSTAT5) in arcuate nucleus kisspeptin neurons in the rat and rostral hypothalamic kisspeptin neurons in the mouse. Chronic infusion of prolactin in female mice abolished estrous cyclicity and suppressed global Gnrh and Kiss1 mRNA expression in the hypothalamus, while kisspeptin therapy restored estrous cycles in hyperprolactinemic mice, consistent with the hypothesis that prolactin-induced suppression of GnRH secretion is mediated by an inhibition of kisspeptin neurons.

Clearly, under most conditions, hyperprolactinemia represents a pathological condition with adverse consequences. During pregnancy and lactation, however, hyperprolactinemia is physiologically appropriate. When viewed from this context, an inhibitory action of prolactin on fertility during pregnancy and lactation would be highly adaptive, allowing the mother to focus energy on feeding her offspring, before investing resources in a further pregnancy. Lactation is associated with a period of infertility in most mammalian females, including women. In humans, this function serves as a critical regulator of population growth, spacing the timing of births to allow the mother to ration her metabolic investment across sequential pregnancies. Despite the extensive impact on mammalian reproductive physiology, our understanding of the mechanisms mediating lactational infertility remains incomplete. It is clear that suckling is the critical inhibitory signal, and the principle cause of infertility is an almost-complete suppression of the pulsatile secretion of GnRH from the hypothalamus, the consequent loss of pituitary gonadotropin secretion and ovulation failure. The pathways linking the suckling stimulus to the suppression of ovulation, however, are unclear. Kiss1 mRNA and protein levels are reduced in the arcuate nucleus of lactating rats associated with the suppression of pulsatile GnRH secretion during lactation, and in both populations in the mouse. The RP3V kisspeptin population is harder to study in rats, with reports of both Kiss1 mRNA remaining unchanged during lactation and of kisspeptin protein increasing while Kiss1 mRNA labeling decreased during lactation. More importantly, we have also shown that the reduction in kisspeptin expression results in complete loss of capacity for these neurons to activate GnRH neurons, even if they are stimulated exogenously. Given the similarity between the effect of suckling and the effect of prolactin, and the knowledge that suckling stimulates prolactin secretion, it seems likely that elevated prolactin during pregnancy and lactation contributes to the infertility of lactation, but this remains to be proven, and the relative roles of prolactin and/or suckling may be different in different species.

What does prolactin do in the male?

The hypothesis that most prolactin actions in the body can be tied to the adaptation to pregnancy and lactation clearly does not explain effects of prolactin in the male. Up to 40% of the male pituitary gland is dedicated to lactotrophs, suggesting that some function is retained in males, but knockout studies have not identified an essential function of prolactin. While there is no male equivalent of lactation, many of the other functions of prolactin in females can also be observed in males. For example, as in females, prolactin seems to be involved in parental behaviour in males, although the relative role that the mammalian father plays in parental care of offspring varies amongst species. In species where the male plays some role in rearing of the offspring, including humans, studies have found a association between prolactin and paternal care, although the overall picture is unclear and controversial. Nevertheless, paternal recognition of offspring is consistent amongst most species. Pup-contact by male rats can lead to some forms of parental care behaviour and this is associated with an increase in serum prolactin, as well as increased expression of the long-form of the prolactin receptor in the brain. Further evidence for a direct role for prolactin in paternal recognition of offspring has been shown by studies of Prlr−/− fathers, who fail to distinguish adult offspring from non-offspring, possibly as a result of failure of prolactin-induced neurogensis in the sub-ventricular zone and the dentate gyrus.

As in females, pathological hyperprolactinemia causes infertility in males, but it is not clear that there is an adaptive role for prolactin in male reproduction. At lower levels, prolactin contributes a range of functions in the male reproductive tract, revealed by subtle reproductive deficits in the prolactin receptor deficient mice. In addition, many of the metabolic and immune functions of prolactin can be observed in males, but whether prolactin levels are ever sufficient for these effects to be of physiological significance is uncertain. Perhaps the most consistent stimulus for prolactin secretion in males is stress, but the functional consequences of this response are not well-understood.

Conclusion

While Harris was correct in proposing that the brain controls prolactin secretion, the hypothalamo-prolactin axis proved itself to be quite different from all other pituitary systems. It remains the most complex and versatile of all of the hypothalamo-pituitary axes. Even if we just consider the relatively simple task of controlling milk production during lactation, there is much that remains to be understood, such as the possible role of one or more prolactin-releasing factors during the suckling stimulus, and the mechanism controlling the loss of dopamine production in the TIDA neurons and the changes in prolactin negative feedback. If we include the wide range of additional functions of prolactin, then the complexity becomes overwhelming. I have presented here a context to attempt to understand the pleiotropic roles of prolactin, arguing that many of the functions of prolactin can be unified into the overall task of maternal adaptation to pregnancy and lactation. Within this context, prolactin function promotes adaptive changes in a variety of body systems, but such actions can also be maladaptive, in a different context, if hyperprolactinemia occurs at an inappropriate time. This theoretical construct presents many new opportunities for generating testable hypotheses about prolactin function. But there are also many functions that do not fit easily into this construct, providing further opportunities for expanding our understanding. I anticipate that the coming availability of novel tools for investigating prolactin function, including gene-targeting approaches that allow conditional regulation of prolactin responsive cells, will provide the impetus for a new wave of research to enhance our understanding of this fascinating system. Sixty years on from Geoffrey Harris' prescient predictions, we still have a lot of work to do to understand the hypothalamo-prolactin system.

Footnote

This paper is part of a thematic review section on 60 years of neuroendocrinology. The Guest Editors for this section were Ashley Grossman and Clive Coen.

References 297

  1. 1.

    Allen DL, Low MJ, Allen RG, Ben-Jonathan N. Identification of two classes of prolactin-releasing factors in intermediate lobe tumors from transgenic mice. Endocrinology. 1995;136:3093-3099.

    Not in our library10.1210/endo.136.7.7789336

  2. 2.

    Anderson GM, Beijer P, Bang AS, Fenwick MA, Bunn SJ, Grattan DR. Suppression of prolactin-induced signal transducer and activator of transcription 5b signaling and induction of suppressors of cytokine signaling messenger ribonucleic acid in the hypothalamic arcuate nucleus of the rat during late pregnancy and lactation. Endocrinology. 2006a;147:4996-5005.

    Not in our library10.1210/en.2005-0755

  3. 3.

    Anderson ST, Barclay JL, Fanning KJ, Kusters DH, Waters MJ, Curlewis JD. Mechanisms underlying the diminished sensitivity to prolactin negative feedback during lactation: reduced STAT5 signalling and upregulation of cytokine-inducible SH2-domain-containing protein (CIS) expression in tuberoinfundibular dopaminergic neurons. Endocrinology. 2006b;147:1195-1202.

    Not in our library10.1210/en.2005-0905

  4. 4.

    Anderson GM, Kieser DC, Steyn FJ, Grattan DR. Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol. Endocrinology. 2008;149:1562-1570.

    Not in our library10.1210/en.2007-0867

  5. 5.

    Andrews ZB. Neuroendocrine regulation of prolactin secretion during late pregnancy: easing the transition into lactation. Journal of Neuroendocrinology. 2005;17:466-473.

    Not in our library10.1111/j.1365-2826.2005.01327.x

  6. 6.

    Andrews ZB, Grattan DR. The roles of dopamine and the neurointermediate lobe of the pituitary in the regulation of prolactin secretion during late pregnancy in rats. Journal of Neuroendocrinology. 2004;16:859-865.

    Not in our library10.1111/j.1365-2826.2004.01241.x

  7. 7.

    Andrews ZB, Kokay IC, Grattan DR. Dissociation of prolactin secretion from tuberoinfundibular dopamine activity in late pregnant rats. Endocrinology. 2001;142:2719-2724.

    Not in our library10.1210/endo.142.6.8196

  8. 8.

    Annunziato L, Moore KE. Prolactin in CSF selectively increases dopamine turnover in the median eminence. Life Sciences. 1978;22:2037-2042.

    Not in our library10.1016/0024-3205(78)90551-9

  9. 9.

    Araujo-Lopes R, Crampton JR, Aquino NS, Miranda RM, Kokay IC, Reis AM, Franci CR, Grattan DR, Szawka RE. Prolactin regulates kisspeptin neurons in the arcuate nucleus to suppress LH secretion in female rats. Endocrinology. 2014;155:1010-1020.

    Not in our library10.1210/en.2013-1889

  10. 10.

    Arbogast LA, Ben-Jonathan N. The preovulatory prolactin surge is prolonged by a progesterone-dependent dopaminergic mechanism. Endocrinology. 1990;126:246-252.

    Not in our library10.1210/endo-126-1-246

  11. 11.

    Arbogast LA, Voogt JL. Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. Endocrinology. 1991a;128:997-1005.

    Not in our library10.1210/endo-128-2-997

  12. 12.

    Arbogast LA, Voogt JL. Mechanisms of tyrosine hydroxylase regulation during pregnancy: evidence for protein dephosphorylation during the prolactin surges. Endocrinology. 1991b;129:2575-2582.

    Not in our library10.1210/endo-129-5-2575

  13. 13.

    Arbogast LA, Voogt JL. Progesterone reverses the estradiol-induced decrease in tyrosine hydroxylase mRNA levels in the arcuate nucleus. Neuroendocrinology. 1993;58:501-510.

    Not in our library10.1159/000126583

  14. 14.

    Arbogast LA, Voogt JL. Progesterone suppresses tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nucleus on proestrus. Endocrinology. 1994;135:343-350.

    Not in our library10.1210/endo.135.1.7912184

  15. 15.

    Arbogast LA, Voogt JL. Prolactin (PRL) receptors are colocalized in dopaminergic neurons in fetal hypothalamic cell cultures: effect of PRL on tyrosine hydroxylase activity. Endocrinology. 1997;138:3016-3023.

    Not in our library10.1210/endo.138.7.5227

  16. 16.

    Arey BJ, Freeman ME. Oxytocin, vasoactive-intestinal peptide, and serotonin regulate the mating-induced surges of prolactin secretion in the rat. Endocrinology. 1990;126:279-284.

    Not in our library10.1210/endo-126-1-279

  17. 17.

    Arey BJ, Freeman ME. Activity of oxytocinergic neurons in the paraventricular nucleus mirrors the periodicity of the endogenous stimulatory rhythm regulating prolactin secretion. Endocrinology. 1992a;130:126-132.

    Not in our library10.1210/endo.130.1.1727695

  18. 18.

    Arey BJ, Freeman ME. Activity of vasoactive intestinal peptide and serotonin in the paraventricular nucleus reflects the periodicity of the endogenous stimulatory rhythm regulating prolactin secretion. Endocrinology. 1992b;131:736-742.

    Not in our library10.1210/endo.131.2.1639019

  19. 19.

    Arey BJ, Averill RL, Freeman ME. A sex-specific endogenous stimulatory rhythm regulating prolactin secretion. Endocrinology. 1989;124:119-123.

    Not in our library10.1210/endo-124-1-119

  20. 20.

    Arey BJ, Kanyicska B, Freeman ME. The endogenous stimulatory rhythm regulating prolactin secretion is present in the lactating rat. Neuroendocrinology. 1991;53:35-40.

    Not in our library10.1159/000125694

  21. 21.

    Arimura A, Dunn JD, Schally AV. Effect of infusion of hypothalamic extracts on serum prolactin levels in rats treated with nembutal, CNS depressants or bearing hypothalamic lesions. Endocrinology. 1972;90:378-383.

    Not in our library10.1210/endo-90-2-378

  22. 22.

    Arita J, Kimura F. Direct inhibitory effect of long term estradiol treatment on dopamine synthesis in tuberoinfundibular dopaminergic neurons: in vitro studies using hypothalamic slices. Endocrinology. 1987;121:692-698.

    Not in our library10.1210/endo-121-2-692

  23. 23.

    Asa SL, Kelly MA, Grandy DK, Low MJ. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology. 1999;140:5348-5355.

    Not in our library10.1210/endo.140.11.7118

  24. 24.

    Augustine RA, Grattan DR. Induction of central leptin resistance in hyperphagic pseudopregnant rats by chronic prolactin infusion. Endocrinology. 2008;149:1049-1055.

    Not in our library10.1210/en.2007-1018

  25. 25.

    Augustine RA, Kokay IC, Andrews ZB, Ladyman SR, Grattan DR. Quantitation of prolactin receptor mRNA in the maternal rat brain during pregnancy and lactation. Journal of Molecular Endocrinology. 2003;31:221-232.

    Not in our library10.1677/jme.0.0310221

  26. 26.

    Augustine RA, Ladyman SR, Grattan DR. From feeding one to feeding many: hormone-induced changes in bodyweight homeostasis during pregnancy. Journal of Physiology. 2008;586:387-397.

    Not in our library10.1113/jphysiol.2007.146316

  27. 27.

    Averill RL, Grattan DR, Norris SK. Posterior pituitary lobectomy chronically attenuates the nocturnal surge of prolactin in early pregnancy. Endocrinology. 1991;128:705-709.

    Not in our library10.1210/endo-128-2-705

  28. 28.

    Bachelot A, Beaufaron J, Servel N, Kedzia C, Monget P, Kelly PA, Gibori G, Binart N. Prolactin independent rescue of mouse corpus luteum life span: identification of prolactin and luteinizing hormone target genes. American Journal of Physiology. Endocrinology and Metabolism. 2009;297:E676-E684.

    Not in our library10.1152/ajpendo.91020.2008

  29. 29.

    Bakowska JC, Morrell JI. Atlas of the neurons that express mRNA for the long form of the prolactin receptor in the forebrain of the female rat. Journal of Comparative Neurology. 1997;386:161-177.

    Not in our library10.1002/(sici)1096-9861(19970922)386:2<161::aid-cne1>3.0.co;2-#

  30. 30.

    Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NM, Beaulieu S, Joober R, Richard D. Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2004;28:1305-1311.

    Not in our library10.1016/j.pnpbp.2004.08.001

  31. 31.

    Barber MC, Clegg RA, Finley E, Vernon RG, Flint DJ. The role of growth hormone, prolactin and insulin-like growth factors in the regulation of rat mammary gland and adipose tissue metabolism during lactation. Journal of Endocrinology. 1992;135:195-202.

    Not in our library10.1677/joe.0.1350195

  32. 32.

    Barraclough CA, Sawyer CH. Induction of pseudopregnancy in the rat by reserpine and chlorpromazine. Endocrinology. 1959;65:563-571.

    Not in our library10.1210/endo-65-4-563

  33. 33.

    Becquet D, Boyer B, Rasolonjanahary R, Brue T, Guillen S, Moreno M, Franc JL, Francois-Bellan AM. Evidence for an internal and functional circadian clock in rat pituitary cells. Molecular and Cellular Endocrinology. 2014;382:888-898.

    Not in our library10.1016/j.mce.2013.11.004

  34. 34.

    Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews. 2001;22:724-763.

    Not in our library10.1210/edrv.22.6.0451

  35. 35.

    Ben-Jonathan N, Oliver C, Weiner HJ, Mical RS, Porter JC. Dopamine in hypophysial portal plasma of the rat during the estrous cycle and throughout pregnancy. Endocrinology. 1977;100:452-458.

    Not in our library10.1210/endo-100-2-452

  36. 36.

    Ben-Jonathan N, Neill MA, Arbogast LA, Peters LL, Hoefer MT. Dopamine in hypophysial portal blood: relationship to circulating prolactin in pregnant and lactating rats. Endocrinology. 1980;106:690-696.

    Not in our library10.1210/endo-106-3-690

  37. 37.

    Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends in Endocrinology and Metabolism. 2006;17:110-116.

    Not in our library10.1016/j.tem.2006.02.005

  38. 38.

    Ben-Jonathan N, Lapensee CR, Lapensee EW. What can we learn from rodents about prolactin in humans? Endocrine Reviews. 2008;29:1-41.

    Not in our library10.1210/er.2007-0017

  39. 39.

    Berghorn KA, Le WW, Sherman TG, Hoffman GE. Suckling stimulus suppresses messenger RNA for tyrosine hydroxylase in arcuate neurons during lactation. Journal of Comparative Neurology. 2001;438:423-432.

    Not in our library10.1002/cne.1325

  40. 40.

    Bjorklund A, Moore RY, Nobin A, Stenevi U. The organization of tubero-hypophyseal and reticulo-infundibular catecholamine neuron systems in the rat brain. Brain Research. 1973;51:171-191.

    Not in our library10.1016/0006-8993(73)90371-5

All 297 references

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.